Special Issues
This review will provide the oncology care team with information on the latest research developments and insights into best practices in treating multiple myeloma to enhance their management of patients with this disease, leading to an improvement in clinical outcomes.
This review will provide the oncology care team with information on the latest research developments and insights into best practices in the use of biosimilars to enhance their management of patients with cancer, leading to an improvement in clinical outcomes.
This review will provide the oncology care team with information on the latest research developments and insights into best practices in treating ovarian cancer to enhance their management of patients with this disease, leading to an improvement in clinical outcomes.
Epithelial ovarian cancer is the fifth leading cause of cancer mortality in women and is the leading cause of death due to gynecologic cancer in the United States.
There have been significant improvements in the survival of patients with metastatic colorectal cancer (mCRC) over the past decade. However, patients with the disease who fail to respond to first- or second-line therapies, including chemotherapy and monoclonal antibodies, have few treatment options. Advances in subsequent treatment lines rather than in first- or second-line therapies now drive improvements in survival for these patients.
Following the advent of molecularly targeted agents, and more recently, immunotherapy, over the past few decades, we have witnessed dramatic changes in the treatment paradigms for many types of cancer. These advancements were driven by molecular profiling that enabled the identification of those patient populations most likely to benefit from targeted therapy and/or immunotherapy—that is, precision medicine.